Journal
CLINICAL RHEUMATOLOGY
Volume 40, Issue 3, Pages 941-948Publisher
SPRINGER LONDON LTD
DOI: 10.1007/s10067-020-05343-6
Keywords
CD163; Lupus nephritis; M2 macrophages; Macrophages; Renal SLEDAI; Urinary biomarkers
Categories
Funding
- Dept. of Biotechnology, Government of India research grant [BT/PR15397/MED/30/604/2011]
- India RheumatologyAssociation (IRA)
Ask authors/readers for more resources
Urinary sCD163 is a promising biomarker for assessing disease activity in lupus nephritis, showing significantly higher levels in active LN patients and correlating with renal SLEDAI. In follow-up studies, urinary sCD163 levels decreased gradually in active LN patients and correlated with disease activity changes, suggesting its potential for monitoring disease progression.
Objectives Activated macrophages expressing CD163 (M2) are the most abundant macrophage subtype in renal biopsies from lupus nephritis (LN) patients. We studied the role of proteolytically cleaved soluble CD163 (sCD163) as a biomarker of LN disease activity. Methods SLE patients were classified as active LN (AN), inactive disease (ID), and active non-renal disease (ANR). Urine and plasma samples were collected at baseline from all patients and at 3 monthly follow-up from AN patients. sCD163 was measured by ELISA. Urine values were normalized to urinary creatinine excretion and expressed as pg/mg. Urine samples from 25 healthy controls (HC) and 20 rheumatoid arthritis patients served as disease controls (DC). Results Among the 122 patients studied (114 females, 57 AN, 42 ID, 23 ANR), baseline median urinary sCD163 in the AN group (114.01 pg/mg) was significantly higher (p < 0.001) as compared with ID (10.34 pg/mg), ANR (3.82 pg/mg), HC (0 pg/mg), and DC (7.56 pg/mg) groups and showed modest correlation with renal SLEDAI (r = 0.47;p < 0.001). Urinary sCD163 performed the best on receiver operating characteristics (ROC) analysis (AUC = 0.76) at baseline to differentiate between AN and ANR as compared with plasma sCD163, anti-ds DNA antibodies, and C3 and C4. In follow-up study, urinary sCD163 decreased significantly (p < 0.001) in AN patients at 3 (22.07 pg/mg), 6 (12.7 pg/mg), 9 (11.09 pg/mg), and 12 months (7.2 pg/mg). In 4 patients who had either relapse or developed CKD, urinary sCD163 levels correlated with the changing disease activity. Conclusions Urinary sCD163 is a good biomarker of LN disease activity.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available